These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24433806)

  • 1. [Rational use of hepato-protectants in the prophylaxis and treatment of anti-tuberculosis drug-induced hepatotoxicity].
    Gu J; Xiao HP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):767-9. PubMed ID: 24433806
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of anti-tuberculosis drug-induced hepatotoxicity.
    Tahaoğlu K; Ataç G; Sevim T; Tärün T; Yazicioğlu O; Horzum G; Gemci I; Ongel A; Kapakli N; Aksoy E
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):65-9. PubMed ID: 11263519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of liver protection drugs in patients with anti-tuberculosis therapy induced liver injury].
    Miao XH
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):729-31. PubMed ID: 24433799
    [No Abstract]   [Full Text] [Related]  

  • 5. Antituberculous therapy and acute liver failure.
    Caplin M; Thompson N; Hamilton M; McIntyre N; Burroughs A
    Lancet; 1995 May; 345(8958):1171. PubMed ID: 7786346
    [No Abstract]   [Full Text] [Related]  

  • 6. [Debate on the prophylactic application of hepatoprotectants during anti-tuberculosis treatment].
    Xiao HP
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):722-3. PubMed ID: 24433796
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of hyperacute hepatotoxicity in response to tuberculosis therapy.
    Hercus CG; Khoo JK; Jones TE
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1709-10. PubMed ID: 23131275
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens.
    Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of stimuliv, an indigenous compound formulation, against hepatotoxicity of antitubercular drugs--a double blind study.
    Dange SV; Shah KU; Bulakh PM; Joshi DR
    Indian J Chest Dis Allied Sci; 1992; 34(4):175-83. PubMed ID: 1302750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of antitubercular drugs-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal.
    Shakya R; Rao BS; Shrestha B
    Kathmandu Univ Med J (KUMJ); 2005; 3(1):45-9. PubMed ID: 16401944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of antituberculosis drugs.
    Mohan A; Sharma SK
    Am J Respir Crit Care Med; 2004 Apr; 169(7):882-3. PubMed ID: 15044223
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinic and pathogenesis of drug hepatitis].
    Mardare G
    Rev Med Chir Soc Med Nat Iasi; 1982; 86(1):43-5. PubMed ID: 25591247
    [No Abstract]   [Full Text] [Related]  

  • 13. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
    Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common risk factors for the development of anti tuberculosis treatment induced hepatotoxicity.
    Abbasi MA; Ahmed N; Suleman A; Zaman H; Tariq S; Anwar SA; Khan N
    J Ayub Med Coll Abbottabad; 2014; 26(3):384-8. PubMed ID: 25671954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regarding "Management of antitubercular drug-induced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal".
    Anupa KC; Bista D
    Kathmandu Univ Med J (KUMJ); 2005; 3(3):310. PubMed ID: 18661667
    [No Abstract]   [Full Text] [Related]  

  • 16. [The hepatotoxicity of antitubercular agents].
    Alegre Martín J; Fernández de Sevilla T
    An Med Interna; 1992 Nov; 9(11):523-5. PubMed ID: 1467398
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors.
    Shakya R; Rao BS; Shrestha B
    Ann Pharmacother; 2004 Jun; 38(6):1074-9. PubMed ID: 15122004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatotoxicity of antimicrobial agents. II: Urinary antiseptics, antitubercular agents, antiparasitic agents, antifungal agents, antiviral agents].
    Horsmans Y; Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1990; 14(12):919-24. PubMed ID: 2289669
    [No Abstract]   [Full Text] [Related]  

  • 19. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients.
    Tostmann A; van den Boogaard J; Semvua H; Kisonga R; Kibiki GS; Aarnoutse RE; Boeree MJ
    Trop Med Int Health; 2010 Feb; 15(2):268-72. PubMed ID: 20409289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paying attention to the prevention and treatment of hepatic injury induced by anti-tuberculosis drugs].
    Tan SY
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):326-329. PubMed ID: 31137107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.